Business
BioMarin Announces Second Quarter 2020 Total Revenue Growth of 11% to $430 million
- Impact of the Coronavirus (COVID-19) Pandemic as Expected in the Second Quarter; 2020 Full-Year Revenue Guidance Reaffirmed Assuming Demand Patterns Return
About this update from Biomarin Pharmaceutical Inc.
[{"type":"text","content":"- Impact of the Coronavirus (COVID-19) Pandemic as Expected in the Second Quarter; 2020 Full-Year Revenue Guidance Reaffirmed Assuming Demand Patterns Return to Normal in Late 2020\n - U.S. Marketing Application for Valoctocogene Roxaparvovec for Severe Hemophilia A under Priority Review by Food and Drug Administration (FDA) with Prescription Drug User Fee Act (PDUFA) Target Action Date of August 21, 2020\n - Marketing Authorization Application (MAA) for Valoctocogene Roxaparvovec for Severe Hemophilia A Validated by the European Medicines Agency (EMA); Committee for Medicinal Products for Human Use (CHMP) Opinion Expected by Late 2020/Early 2021\n - MAA Submitted to EMA for Vosoritide to Treat Children with Achondroplasia July 23; On track to Submit a New Drug Application (NDA) to the FDA Late in the Third Quarter of 2020\n - For the Full-Year 2020 BioMarin Continues to Expect to be Profitable on a GAAP Basis for the First Time\n\n\n\n \n \n SAN RAFAEL, Calif., Aug. 4, 2020 /PRNewswire/ --\n\n \n \n \n \n \n \n\n \nFinancial Highlights (in millions of U.S. dollars, except per share data, unaudited)\nThree Months Ended June 30,\nSix Months Ended June 30,\n2020\n2019\n% Change\n2020\n2019\n% Change\nTotal Revenues\n$\n429.5\n$\n387.8\n11\n%\n$\n931.6\n$\n788.5\n18\n%\nNet Product Revenues Marketed by BioMarin (1)\n386.8\n373.3\n4\n%\n820.1\n722.5\n14\n%\nVimizim Net Product Revenues\n116.7\n122.7\n(5)\n%\n253.9\n248.5\n2\n%\nKuvan Net Product Revenues\n122.6\n113.3\n8\n%\n244.6\n220.2\n11\n%\nNaglazyme Net Product Revenues\n81.0\n98.2\n(18)\n%\n195.3\n185.1\n6\n%\nPalynziq Net Product Revenues\n40.7\n18.8\n116\n%\n75.3\n31.1\n142\n%\nBrineura Net Product Revenues\n25.8\n14.8\n74\n%\n49.8\n27.0\n84\n%\nAldurazyme Net Product Revenues\n32.3\n5.8\n457\n%\n88.0\n51.1\n72\n%\nGAAP Net Income (Loss)\n$\n(29.2)\n$\n(37.4)\n$\n52.2\n$\n(93.9)\nGAAP Net Income (Loss) per Share – Basic\n$\n(0.16)\n$\n(0.21)\n$\n0.29\n$\n(0.53)\nGAAP Net Income (Loss) per Share – Diluted\n$\n(0.16)\n$\n(0.21)\n$\n0.28\n$\n(0.53)\nNon-GAAP Income (2)\n$\n57.4\n$\n17.1\n$\n173.9\n$\n42.2\n \nJune 30,2020\nDecember 31,2019\nCash, cash equivalents and investments\n$\n1,703.4\n$\n1,165.8\n(1)\nNet Product Revenues Marketed by BioMarin is the sum of revenues from Vimizim, Kuvan, Naglazyme, Palynziq, Brineura and Firdapse, each calculated in accordance with Genera...